Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 6/20 | 0.49 |
| ▸ | MTOR | P42345 | 10/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.49 |
| ▸ | ABL1 | P00519 | 3/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | HCK | P08631 | 3/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.49 |
| ▸ | PRKDC | P78527 | 3/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.48 |
| ▸ | YES1 | P07947 | 1/20 | 0.47 |
| ▸ | FGR | P09769 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1320126 | 0.85 | SRC (0.55) | SRCMTORHDAC1PIK3CDABL1 | |
| SCHEMBL13019921 | 0.84 | PIK3CD (0.60) | SRCMTORPIK3CDABL1EGFR | |
| SCHEMBL12123449 | 0.82 | SRC (0.51) | SRCMTORHDAC1PIK3CDABL1 | |
| SCHEMBL24096507 | 0.82 | CYP1A2 (0.59) | SRCMTORPIK3CDABL1EGFR | |
| SCHEMBL12120631 | 0.81 | SRC (0.47) | SRCMTORHDAC1PIK3CDABL1 | |
| SCHEMBL1319408 | 0.80 | NUDT14 (0.59) | SRCMTORPIK3CDABL1EGFR | |
| SCHEMBL24862275 | 0.80 | FGFR1 (0.79) | FGFR2FGFR1FGFR4FGFR3 | |
| SCHEMBL15916593 | 0.78 | BTK (0.67) | SRCEGFRHCKYES1FGR | |
| SCHEMBL29780889 | 0.78 | SRC (0.64) | SRCMTORPIK3CDABL1EGFR | |
| SCHEMBL29998165 | 0.75 | MTOR (0.61) | SRCMTORHDAC1PIK3CDABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358720-B1 | FUSED RING HETEROARYL KINASE INHIBITORS | UNIV CALIFORNIA (US) | 2016-03-02 | — | — | EP | disclosed |
| US-8980899-B2 | Methods of inhibiting Ire1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-17 | — | — | US | disclosed |
| US-8697709-B2 | Fused ring heteroaryl kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-04-15 | — | — | US | disclosed |
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-20 | — | — | US | disclosed |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | XBP1, DNAJC10, HSPA5 | SRC 4225/4885MTOR 3179/4885HDAC1 3480/4885 |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | CNKSR1, MAP3K20, TTK | SRC 180/4885MTOR 400/4885HDAC1 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.